Familial combined hyperlipidemia: Consensus document;Hiperlipidemia familiar combinada: documento de consenso

Atencion Primaria

Volumn 46, Issue 8, 2014, Pages 440-446

  Mata, Pedro ^a   Alonso, Rodrigo ^b   Ruíz Garcia, Antonio ^c   Díaz Díaz, Jose L ^d   González, Noemí ^e   Gijón Conde, Teresa ^f   Martínez Faedo, Ceferino ^g   Morón, Ignacio ^h   Arranz, Ezequiel ⁱ   Aguado, Rocío ^j   Argueso, Rosa ^k   Perez De Isla, Leopoldo ^l  

^a Medicina Interna   (Spain)

^b UAM)   (Spain)

^c Centro de Salud Pinto   (Spain)

^d Hospital Abente y Lago   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^g HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^h Centro de Salud Goya 2   (Spain)

ⁱ Centro de Salud San Blas   (Spain)

^j HOSPITAL UNIVERSITARIO DE LEÓN   (Spain)

^k Hospital de Lugo   (Spain)

^l HOSPITAL CLÍNICO SAN CARLOS   (Spain)

more..

Author keywords

Cardiovascular disease; Consensus paper; Familial combined hyperlipidemia; Hypertension; Lipid lowering treatment; Type 2 diabetes mellitus

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIOVASCULAR RISK; CONSENSUS; DISEASE ASSOCIATION; FAMILIAL COMBINED HYPERLIPIDEMIA; FAMILIAL HYPERLIPEMIA; FAMILY HISTORY; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ALGORITHM; CONSENSUS DEVELOPMENT; HUMAN; HYPERLIPIDEMIA, FAMILIAL COMBINED; PRACTICE GUIDELINE;

ALGORITHMS; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; PRACTICE GUIDELINES AS TOPIC;

EID: 84908252517     PISSN: 02126567     EISSN: 15781275     Source Type: Journal    
DOI: 10.1016/j.aprim.2014.04.013     Document Type: Article

References (32)

1. J.L. Goldstein, H.G. Schrott, W.R. Hazzard, E.L. Bierman, and A.G. Motulsky Hyperlipidemia in coronary artery disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia J Clin Invest 52 1973 1544 1568
2. K.V.K. Porkka, I. Nuotio, P. Pajukanta, C. Ehnholm, L. Suurinkeroinen, and K. Syvänne Phenotype expression in familial combined hyperlipidemia Atherosclerosis 133 1997 245 253
3. A. Gaddi, A.F.G. Cicero, A. Poli, and R. Paoletti Practical guidelines for familial combined hyperlipidemia diagnosis: An up-date Vasc Health Risk Manag 3 2007 877 886
4. P.N. Hopkins, G. Heiss, R.C. Ellison, M.A. Province, J.S. Pankow, and J.G. Eckfeld Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: A case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study Circulation 108 2003 519 523
5. F. Wiesbauer, H. Blessberger, D. Azar, G. Goliasch, O. Wagner, and L. Gerhold Familial-combined hyperlipidaemia in very young myocardial infarction survivors (< or = 40 years of age) Eur Heart J 30 2009 1073 1079
6. M.C. Brouwers, M.M. van Greevenbroek, V.M. Vermeulen, J.M. van Lin, C.J. van der Kallen, and T.W. de Bruin Five-year follow up of waist circumference, insulin and ALT levels in familial combined hyperlypidaemia Clin Sci (Lond) 113 2007 375 381
7. J. Skoumas, L. Papadimitriou, C. Pitsavos, C. Masoura, N. Giotas, and C. Chrysohoou Metabolic syndrome prevalence and characteristics in Greek adults with familial combined hyperlipidemia Metabolism 56 2007 135 141
8. M.C. Brouwers, M.E. Kho, G.P. Browman, J.S. Burgers, F. Cluzeau, and G. Feder AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in health care CMAJ 182 2010 E839 E842
9. J. Andrews, G. Guyatt, A.D. Oxman, P. Alderson, P. Dahm, and Y. Falck-Ytter GRADE guidelines: 15. Going from evidence to recommendations: The significance and presentation of recommendations J Clin Epidemiol 66 2013 719 725
10. M. Brouwers, J. van Greevenbroek, C. Stehouwer, J. de Graaf, and A. Stalenhoef The genetics of familial combined hyperlipidaemia Nat Rev Endocrinol 8 2012 352 362
11. A.D. Sniderman, M. Castro Cabezas, J. Ribalta, R. Carmena, T.W. de Bruin, and J. de Graaf A proposal to redefine familial combined hyperlipidaemia - Third workshop on FCH held in Barcelona from 3 to 5 May 2001, during the Scientific Sessions of the European Society for Clinical Investigation Eur J Clin Invest 32 2002 71 73
12. M.J. Veerkamp, J. de Graaf, S.J.H. Bredie, J.C.M. Hendricks, P.N.M. Demacker, and A.F.H. Stalenhoef Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families Arterioscler Thromb Vasc Biol 22 2002 274 282
13. M.J. Veerkamp, J. de Graaf, J.C.M. Hendriks, P.N.M. Demacker, and A.F.H. Stalenhoef Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study Circulation 109 2004 2980 2985
14. A.L. Catapano, Z. Reiner, G. de Backer, I. Graham, M.-R. Taskinen, and O. Wiklund ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 2011 3 46
15. J. Perk, G. de Backer, H. Gohlke, I. Graham, Z. Reiner, and M. Verschuren European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Atherosclerosis 223 2012 1 68
16. R. Estruch, E. Ros, J. Salas-Salvadó, M.-I. Covas, D. Corella, and F. Arós Primary prevention of cardiovascular disease with a Mediterranean diet N Engl J Med 368 2013 1279 1290
17. Cholesterol Treatment Trialists' CTT Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170.000 participants in 26 randomised trials Lancet 376 2010 1670 1681
18. C.M. Ballantyne, J. Houri, A. Notarbartolo, L. Melani, L.J. Lipka, and R. Suresh Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial Circulation 107 2003 2409 2415
19. J.C. Ansquer, I. Bekaert, M. Guy, M. Hanefeld, and A. Simon Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: A prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study Am J Cardiovascu Drugs 9 2009 91 101
20. J. Millán, E. Alegría, C. Guijarro, J.V. Lozano, G.C. Vitale, and B. González-Timón Dyslipemia in diabetics treated with statins. Results of the dyslipidemia international study in Spain Med Clin (Barc) 141 2013 430 436
21. I. Skoumas, C. Masoura, K. Aznaouridis, V. Metaxa, A. Tsokanis, and L. Papadimitriou Impact of cardiometabolic risk factors on major cardiovascular events in patients with familial combined hyperlipidemia Circ J 77 2013 163 168
22. Executive summary: Standards of medical care in, diabetes - 2013 Diabetes Care 36 Suppl 1 2013 S4 S10
23. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, and M. Nauck Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
24. F.M. Turnbull, C. Abraira, R. Anderson, R.P. Byington, J.O. Chalmers, and W.C. Duckworth Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 52 2009 2288 2298
25. J. Salas-Salvadó, M. Bulló, R. Estruch, E. Ros, M.I. Covas, and N. Ibarrola-Jurado Prevention of diabetes with Mediterranean diets: A subgroup analysis of a randomized trial Ann Intern Med 160 2014 1 10
26. Prospective Diabetes Study (UKPDS) Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 1998 854 865
27. O.J. Phung, J.M. Scholle, M. Talwar, and C.I. Coleman Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes JAMA 303 2010 1410 1418
28. O.J. Phung, E. Schwartzman, R.W. Allen, S.S. Engel, and S.N. Rajpathak Sulphonylureas and risk of cardiovascular disease: Systematic review and meta-analysis Diabet Med 30 2013 1160 1171
29. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, and B. Hirshberg Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 369 2013 1317 1326
30. T. Karagiannis, P. Paschos, K. Paletas, D.R. Matthews, and A. Tsapas Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: Systematic review and meta-analysis BMJ 344 2012 e1369 10.1136/bmj.e1369
31. G. Mancia, R. Fagard, K. Narkiewicz, J. Redón, A. Zanchetti, and M. Böhm 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology(ESC) J Hypertens 31 2013 1281 1357
32. A. De la Sierra, M. Gorostidi, R. Marín, J. Redón, J.R. Banegas, and P. Armario Evaluación y tratamiento de la hipertensión arterial en España. Documento de consenso Med Clin 131 2008 104 116